Migraine: Molecular Basis and Herbal Medicine by Mohammad Ansari et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
8 
Migraine: Molecular Basis and Herbal Medicine 
Mohammad Ansari1,2*, Kheirollah Rafiee1,  
Solaleh Emamgholipour1 and Mohammad-Sadegh Fallah3  
1Department of Medical Biochemistry, Tehran University of Medical Sciences, Tehran, 
2Araamesh Multi-Professional Pain Clinic, Tehran, 
3Kawsar Human Genetics Research Center (KHGRC), Tehran, 
Iran  
1. Introduction 
Migraine is a common and disabling brain disorder with no single characteristic which 
could be used for a definite diagnosis. Usually a combination of different presentations is 
used as diagnostic criteria which may lead to a challenging feature of under- or 
misdiagnosis and also under-treatment. Diagnostic criteria for migraine usually emphasize 
on specificity compared to sensitivity which enhances their research values but reduces their 
clinical worth. The criteria are subjective and the lack of objective tests to confirm migraine 
diagnosis raises the need of rule out of other diagnoses. For this reason a potential 
diagnostic biomarker for migraine would certainly find wide application and may improve 
current severe deficiencies in migraine diagnosis.  
1.1 Definition and classification 
The term migraine is originated from Greek word “hemicrania” (Silberstein, 2004), meaning 
“one side of the head”. Migraine headache as an episodic neurovascular phenomenon is 
characterized by recurrent attacks of unilateral headache (Silberstein, 2004) while headache is 
recognized as the most well-known symptom of migraine, its origin generally remains unclear 
(Messlinger, 2009). A combination of genetic and environmental factors contributes to the 
onset, progression, and severity of headache (Pietrobon & Striessnig, 2003). Migraine is 
classified into two major types — migraine without aura and migraine with aura (ICHD, 2004). 
1.1.1 Migraine without aura  
Migraine without aura (previously known as hemicrania simplex, common migraine) is a 
specific neurological disorder characterized by unilateral, pulsating quality, aggravation on 
movement, and moderate to severe headache, nausea and photophobia. Most migraineurs 
suffer from this subtype of migraine, and there are higher frequency and more severe attacks 
in comparison with migraine with aura. Owing to strong relationship between migraine 
without aura with menstrual cycle, the menstrual migraine (i.e. pure menstrual migraine and 
menstrually-related migraine) is categorized in this subtype. In pure menstrual migraine in 
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contrast to other types, migraine headaches are strictly restricted to the perimenstrual phase 
and do not happen at other times of the menstrual cycle (ICHD, 2004). 
1.1.2 Migraine with aura  
Migraine with aura (formerly known as classical migraine, ophthalmic, hemiplegic 
migraine) is defined as a recurrent disorder involving headache attacks appearing gradually 
over 5-20 minutes and lasting for less than 60 minutes. The aura encompasses focal 
neurological symptoms that precede or accompany at the onset of migraine attacks. Aura 
can involve reversible visual and sensory symptoms and speech weakness. Inherited forms 
of familial hemiplegic migraine and sporadic hemiplegic migraine, in which patients suffer 
from motor weakness, are classified in this subtype (ICHD, 2004). 
1.2 Epidemiology and burden of health 
The worldwide prevalence of headache for all age-group is considered to be more than 47%, 
and of migraine is 10.3% (Jensen & Stovner, 2008). In the United States around 6% of men 
and 18% of women experience at least one migraine attack in a given year. Before puberty, 
there is generally no sex difference (Jensen & Stovner, 2008), but incidence rate generally 
increases with age, especially in girls, until mid-puberty and then declines (Jensen & 
Stovner, 2008; Silberstein, 2004). In different ethnicity Europeans have the higher incidence 
rate followed by African-Americans and Asian-Americans (Silberstein, 2004). 
It is obvious that migraine has a severe negative influence on quality of life (Silberstein, 
2004). Because of its impact on health status, migraine is ranked as one of the top 20 causes 
of healthy life lost and disability by World Health Organization (WHO) (ICHD, 2004). 
Migraine annual cost for employers is about 13$ billion in the USA. Direct annual medical 
cost is over 1$ billion (Silberstein, 2004). 
1.3 Comorbidity 
In medicine, comorbidity describes the presence of one or more separate conditions that 
exists simultaneously in the same individuals (Jensen & Stovner, 2008; Scher et al., 2005). In 
general, the current global prevalence of tension-type headache in patients with migraine is 
94%, of which 56% suffer frequent episodic tension-type headache (Jensen & Stovner, 2008). 
There is a growing evidence for a link between migraine and other diseases, including 
stroke, hypertension, diabetes, asthma, and obesity (Jensen & Stovner, 2008), as well as 
epilepsy (Scher et al., 2005). It is noted that migraine has been related to various indefinite 
disorders such as fibromyalgia, non-headache pain (lower back pain or local muscle pain) 
(Jensen & Stovner, 2008), some congenital heart defects like patent foramen ovalea, anxiety, 
and depression (Scher et al., 2005). 
2. Molecular basis 
2.1 Pathogenesis 
Migraine was once considered to be a vascular phenomenon resulting from intracranial 
vasoconstriction and rebound vasodilation. However, recently it has been suggested that 
neurogenic process leads to a vascular change and consecutive alteration in cerebral 
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perfusion (neurovascular theory) (Pietrobon & Striessnig, 2003). Historically Ebn-e-sina 
(Avicenna, 980–1037) was actually the first medical scientist who addressed neurovascular 
theory of migraine in the Canon of Medicine, which was published centuries ago. It seems 
that this fact has been ignored in recent articles considering history of theories of 
pathogenesis of migraine (Abokrysha, 2009). 
Although the underlying cause of migraines has remained unknown, many biological 
events have been associated with migraine attacks. A potential cause of migraine is any 
change in the stability of pathways either directly or via trigeminocervical pain system. This 
could be inherited as a low activation threshold.  
Cortical spreading depression is another theory that could result in aura by a spreading 
wave of depolarization (Lauritzen M, 1994). Aura is accompanied with a localized decrease 
followed by an increase in blood flow in parieto-occipital cortex (Charles, 2009) which leads 
to activation followed by depression of neurological activity over a cortical area. It could 
result in the release of some inflammatory mediators that irritates cranial nerves root, 
mostly the trigeminal nerve that transmits the sense of face and most of the head. There are 
some experiments supporting involvement of cortical event in the initiation of headache as 
well (Bartleson & Cutrer, 2010). 
Migraine has a strong (up to 50%) genetic component, which is higher in migraine with aura 
than migraine without aura, with a probable multifactorial polygenic inheritance. Genetic 
load can be considered as a determinant that is modulated by external and internal factors 
(migraine triggers) (Pietrobon & Striessnig, 2003). Also, it has been reported that not only 
genes are involved in migraine, but also their protein encoded by them and their 
metabolites (known as biomarkers) may be important in its etiology (Loder, 2006). 
2.2 Biomarkers in migraine 
2.2.1 Definition and classification 
Biological markers (biomarkers) have been defined as biological characteristics that can be 
objectively measured and evaluated as the indicator of normal biological processes, pathogenic 
processes, or pharmacological responses to a therapeutic intervention (Mayeux, 2004). 
It has been shown that changes in the level of some molecules, arising from deficiency, 
increase or impairments of regulatory processes in their production pathway might be 
associated with etiology of migraine. Although, it is unknown that these changes can result 
from or/result in migraine. 
In migraine, different biomarkers including genetic, and/or biochemical have been used for 
diagnosis and/or study of the pathophysiology of the disorder. The term of biomarkers in 
migraine can be classified in two different categories. Biomarkers of exposure or “antecedent 
biomarkers” (such as genetic biomarkers) defined as factors that exist before the development 
of migraine. The levels of these biomarkers are linked to increase or decrease in migraine 
susceptibility. On the contrary, biomarkers of disease can be defined as factors, used as the 
indicators of the presence or development of migraine. They can be used to screen the 
individuals with migraine and prediction of treatment response. In addition, the biomarkers in 
migraine can be classified into groups, based on the types of measured markers, such as genes, 
proteins and metabolites patterns in various body fluids (Loder, 2006). According to these 
categories, all genetic, and proteomic and metabolomic biomarkers are discussed later. 
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2.2.2 Genetic biomarkers 
They are defined as genetic variations (mutations or polymorphisms) that can predict 
disease susceptibility, and help in early diagnosis of migraine, course of disease, disease 
severity and/or response to therapy. Some mutations that were found to be related with 
hemiplegic migraine (de Vries et al., 2006, 2009), and common migraine (Lafrenière et al., 
2010), are good examples of mutation biomarkers. Some polymorphisms were also found to 
be more valuable for screening patients with higher susceptibility into migraine attack in the 
future (De Vries et al., 2006). 
2.2.2.1 The mutation biomarkers in migraine 
2.2.2.1.1 Hemiplegic migraine  
Apart from familiarity—i.e., no affected relatives vs. affected first degree or second-degree 
relative(s), familial hemiplegic migraine is comparable in diagnostic criteria to sporadic 
hemiplegic migraine (Russell & Ducros, 2011). 
2.2.2.1.1.1 Familial hemiplegic migraine 
The familial hemiplegic migraine phenotype is associated with autosomal dominant 
mutations in the CACNA1A, ATP1A2 and SCN1A genes. These familial forms of migraine 
caused by mutations in these genes are referred to FHM1, FHM2, and FHM3, respectively 
(de Vries et al., 2009; Russell & Ducros, 2011). CACNA1A gene is located on 19p13 and 
encodes the main subunit of Cav2.1 neuronal channels. Most of these mutations are 
missense which account for 50-75% of mutations in FHM families (De Vries et al., 2006). 
The CACNA1A T666M mutation is the most frequent cause of familial hemiplegic 
migraine. Interestingly, CACNA1A mutations are also found in other disease, such as 
episodic ataxia type 2 (EA-2) and spinocerebellar ataxia type 6 (SCA-6) (De Vries et al., 
2006). 
The ATP1A2 gene is located on 1q23. This gene encodes the ┙2 subunit of sodium-potassium 
pumps. Several diseases such as basilar-type migraine and common migraine are associated 
with mutations in the ATP1A2 gene (de Vries et al., 2006; 2009).   
The SCN1A gene is located on 2q24 and encodes the ┙1 subunit of the neuronal voltage-
gated sodium channel Nav1.1. It is suggested that Mutations in this gene account for 
generalized epilepsy with febrile seizures plus (GEFS+) and severe myoclonic epilepsy of 
infancy (SMEI) (de Vries et al., 2006; 2009). 
Recently it has been shown that mutation in the SLC1A3, encoding the glial glutamate 
transporter EAAT1 is responsible for pure hemiplegic migraine. Also, a homozygous 
deletion in SLC4A4, encoding the electrogenic sodium bicarbonate (Na+–HCO3–) 
cotransporter NBCe1 was associated with familial hemiplegic migraine. SLC1A3 and 
SLC4A4 seem to be the fourth and fifth genes (FHM4 and FHM5) which are involved in 
familial hemiplegic migraine (Russell & Ducros, 2011). 
Functional studies have shown that FHM mutations cause (i) an enhancement of Ca2+ 
influx via Cav2.1 channels leading to an enhanced release of glutamate, at least in the 
cortex (in the case of CACNA1A mutations), (ii) a dysfunction in glial uptake of K+ and 
glutamate from the synaptic cleft (in the case of ATP1A2 mutations), and (iii) an 
enhanced recovery from fast inactivation and in that way an increased firing rate of 
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neurons (in the case of SCN1A mutations). Therefore, as mentioned above, an increase of 
extracellular glutamate and K+ levels in the synaptic cleft is associated with FHM 
mutations. Neurons may depolarize in a more straightforward manner to facilitate 
cortical spreading depression (de Vries et al., 2006; 2009). It could well explain the aura 
in these monogenic subtypes (de Vries et al., 2009). The findings in FHM support that 
dysfunction in ion transport is a crucial factor in migraine pathophysiology and might 
facilitate the identification of molecular pathways involved in migraine (de Vries et al., 
2006; 2009). 
2.2.2.1.1.2 Sporadic hemiplegic migraine 
Sporadic cases of hemiplegic migraine can result from a de-novo mutation in genes related 
to the FHMs or by inheritance of a gene mutation from an asymptomatic parent (due to 
incomplete penetrance) (Russell & Ducros, 2011).  
Up to now, only a few CACNA1A and ATP1A2 mutations have been reported in patients 
with the sporadic hemiplegic migraine. For that reason, it is suggested that these genes have 
negligible role in pure sporadic hemiplegic migraine. A comparable nomenclature with 
familial hemiplegic migraine is also used for sporadic hemiplegic migraine, too. 
Accordingly, mutations in the CACNA1A and ATP1A2 genes are referred to as sporadic 
hemiplegic migraine (SHM1 and SHM2, respectively) (Russell & Ducros, 2011). 
2.2.2.1.2 Common migraine 
Contrary to hemiplegic migraine, common forms of migraine are a genetically complex 
disorder with higher prevalence, genetic and phenotypic heterogeneity. Like other 
complex genetic traits, finding responsible genes are much more difficult (de Vries et al., 
2006). Despite these problems and absence of any evidence of association between genes 
encoding the ion channels and common migraine in previous studies (Nyholt et al., 2008), 
it has been reported recently that there is a strong genetic link to common forms of 
migraine (Lafrenière et al., 2010). Using a candidate gene approach and functional 
analysis, researchers have identified a mutation, F139wfsX24, in the gene encoding the 
two-pore domain potassium channel TRESK (TWIK-related spinal cord potassium 
channel) KCNK18 in the patients with migraine with aura. The TRESK is involved in pain 
pathways and regulates neuronal excitability. The mutation can lead to a complete loss of 
channel function (Lafrenière et al., 2010) and for the first time, a common form of 
migraine is linked to a genetic mutation (Wood, 2010). The agonist-promoted up-
regulation of TRESK activity can act as a beneficial treatment option, either as an acute 
therapy or as a long-term preventive approach for individuals with migraine (Lafrenière 
et al., 2010). 
Recently, in a genome-wide association study, evidence for association of common forms of 
migraine and rs1835740 on chromosome 8q22.1 has been reported. It has been claimed that 
this is the first relationship between genetic and common forms of migraine, particularly 
migraine with aura. This allele, is located between astrocyte elevated gene 1 (MTDH/AEG-1) 
and plasma glutamate carboxypeptidase (PGCP). Due to the role of these two genes in 
glutamate homeostasis, it seems that complementary pathways such as the glutamate 
system could fasten mendelian channelopathies with pathogenesis of common forms of 
migraine (Anttila et al., 2010). 
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2.2.2.2 Polymorphisms in migraine  
Many positive associations have been reported in different linkage studies between common 
forms of migraine and polymorphisms. However, these results mainly have not been 
replicated, and are therefore of less clinical value (de Vries et al., 2006; 2009). 
Methylenetetrahydrofolate reductase gene MTHFR 677C>T polymorphism and angiotensin 
I-converting enzyme ACE D/I polymorphism are two good examples for genetic association 
with migraine. Methylenetetrahydrofolate reductase is a key enzyme in folate and 
homocysteine metabolism and angiotensin-converting enzyme is an exopeptidase that 
catalyses the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor (Colson 
et al., 2006). 
A meta-analysis study has shown that the MTHFR 677TT genotype was associated with 
increased risk of migraine with aura and ACE II genotype is protective against both 
migraines with and without aura. Due to high heterogeneity among studies, both variants 
appeared to be correlated with common forms of migraine only among non-Caucasian 
populations (Schürks et al., 2010). However, further studies may be required among other 
ethnicities. Previously it has been shown that ACE and MTHFR genes act synergistically as a 
genetic risk of migraine and having at least one copy of the ACE D allele beside the MTHFR 
TT genotype increases the risk of migraine with aura by ~3 fold (Roda, 2005). 
Another meta-analysis study about serotonin transporter gene (5-HTT) variants (including 
5-HTTLPR, VNTR and SNP) indicates that only the VNTR polymorphism is associated with 
an increased risk of migraine (Liu et al., 2011). Existing evidences indicate that the genetic 
polymorphisms in serotonergic system, dopaminergic system, gamma amino butyric acid 
receptor system, inflammation related genes (de Vries et al., 2009), inducible nitric oxide 
synthase promoter (Jia et al., 2011), hypocretin-1 (also termed orexin-A) receptor (Rainero et 
al., 2011), and Notch 3 gene (G684A variant) (Menon et al., 2010) are associated with an 
increased risk of migraine. Other studies suggest that some haplotypes related to 
endothelial nitric oxide synthase (Gonçalves et al., 2011) and vascular endothelial growth 
factor (Gonçalves et al., 2010) could affect the susceptibility to migraine. So genotyping of 
only one polymorphism might not be sufficient and haplotype analysis may be needed to 
elucidate the association between migraine and these polymorphisms. Future studies with 
larger sample sizes will be necessary to confirm the present results. 
2.2.3 Proteomic and metabolomic biomarkers 
Principally, the global analysis of metabolites (metabolomics) and proteins (proteomics) in 
body fluids and tissues can provide certain advantages in understanding the underlying 
mechanisms of migraine. The proteomic and metabolomic signature, mostly belong to 
biochemical markers (such as proteins, peptides, amino acids, and amines), can identify a 
putative disease fingerprint for migraine in blood, urine and cerebrospinal fluid (Loder, 
2006). The list of these biomarkers has been discussed in several reviews (Edvinsson, 2006; 
Harrington, 2006; Loder et al, 2006). 
2.2.3.1 Calcitonin gene-related peptide 
Calcitonin gene related peptide is a 37-amino acid neuropeptide that is a member of the 
calcitonin family of peptide. Calcitonin gene related peptide plays an important role in the 
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modulation of physiological functions such as regulation of vascular tone and modulation of 
pain perception (Durham, 2006; Fischer, 2010). 
Calcitonin gene related peptide was originally thought to contribute to migraine and 
elevated level of this peptide has been reported in this disease (Arulmani et al. 2004; 
Durham, 2006; Fischer, 2010). Calcitonin gene related peptide can lead to enhancement of 
cerebral circulation, transmission of pain-related impulses and neurogenic inflammation 
(Durham, 2006). In fact, in the endothelium dependent and independent (binding to its 
receptors on the smooth muscle cells) pathways, calcitonin gene related peptide activates 
adenylate cyclase and enhanced cyclic adenosine mono phosphate production is believed to 
be involved in increase of blood circulation. Moreover, the cyclic adenosine mono 
phosphate production can cause enhancement of nitric oxide synthase activity and nitric 
oxide production followed by increase in cyclic guanosine mono phosphate production as a 
secondary messenger for nitric oxide. The enhancement of cyclic guanosine mono 
phosphate production was connected to vasodilation and increase in cerebral circulation 
(Arulmani et al., 2004). It is believed that the effects of calcitonin gene related peptide on 
enhancement of substance P release and excitatory amino acids such as glutamate play an 
important role in transmission of calcitonin gene related peptide- mediated pain impulses. 
Also, it seems that calcitonin gene related peptide - mediated neurogenic inflammation is 
followed by degranulation of mast cells and the release of inflammatory agents (Durham, 
2006). 
2.2.3.2 Serotonin  
Serotonin or 5-hydroxytryptamine is synthesized from tryptophan, in various tissues 
including brain (Hamel, 2007). Additionally, this molecule could be found in some plants 
(Badria, 2002). The fluctuations of platelet and plasma level of 5-hydroxytryptamine 
(Panconesi, 2008), change in lymphoblastic serotonin level (Nagata et al., 2007) and number 
of 5-hydroxytryptamine platelet transporters (as indirect index of 5-hydroxytryptamine 
recovery) (Panconesi, 2008) have been reported in patients with migraine. There are some 
controversies regarding the role of serotonin in migraine. It has been shown that there are 
the gender and seasonal variations of serotonin neurotransmission in human such as 5-
hydroxytryptamine receptor hypersensitivity and its decreased cerebrospinal fluid level in 
women and 5-hydroxytryptamine receptor hyposensitivity in summer. On the other hand, 
the higher frequency of migraine in women and higher frequency of its attacks in summer 
compared with winter and autumn has been reported in most studies. Also, nowadays, the 
triptan, a selective serotonin 5-hydroxytryptamine (1B/1C) agonist is being used in the 
treatment of acute migraine attacks. In spite of controversial results about mentioned issues, 
the importance of the failure of a serotonergic system in migraine pathogenesis is 
significant. Accordingly, the serotonin system is considered to be involved in migraine 
(Panconesi, 2008). Moreover, additional studies are necessary to establish its importance in 
migraine etiology.  
2.2.3.3 Melatonin 
The synthesis of melatonin or N-acetyl-5-methyoxytryptamine from serotonin occurs in the 
pineal gland and other tissues in humans (Pandi-Perumal et al., 2006). In addition to the 
vertebrates, this indnole amine has been identified in numerous taxa including bacteria, 
unicellular eukaryotes (Hardeland et al., 2011; Pandi-Perumal et al., 2006) and plants (Ansari 
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et al., 2010; Chen et al., 2003). In vertebrates, the production of melatonin reaches to its peak 
in the darkness and the light inhibits its secretion. Also, age-related decreases in melatonin 
synthesis and secretion have been reported (Pandi-Perumal et al., 2006). Most studies 
indicate that melatonin may play a significant role in sleep and circadian rhythm regulation, 
improvement of immune system (Hardeland et al., 2011) and antioxidant activity (Tan et al., 
2007). 
It has been found that plasma and urinary levels of melatonin (Peres et al., 2006) and 
nocturnal urinary 6-sulfatoxymelatonin concentration (Masruha et al., 2008) decrease in 
patients with migraine. Melatonin receptors are present in trigeminal ganglion and 
trigeminal nucleus of mammals that could explain its action. Also trigeminovascular 
nociception that is induced by cortical spreading depression in rats is attenuated by 
melatonin (Ambriz-Tututi et al., 2009). Therefore, melatonin has been suggested as a 
possible biomarker for migraine (Loder et al., 2006) and there is a great potential for using 
melatonin in acute or prophylactic treatment of migraine headache (Miano et al., 2008; Peres 
et al., 2004). Melatonin seems to be related with migraine pathogenesis in many ways, 
including its anti-inflammatory and antioxidant effects such as reduction in  pro-
inflammatory factors and scavenging toxic free radicals, potentiation of gamma amino 
butyric acid and opioid analgesia, suppression of nitric oxide synthase activity, inhibition of 
dopamine release, protection against glutamate neurotoxicity, and regulation of 
neurovascular regulation (Peres, 2005; Peres et al., 2007). 
2.2.3.4 Nitric oxide  
Nitric oxide as a diatomic molecule is synthesized by nitric oxide synthases from L-arginine. 
Changes in plasma and platelet (Gallai et al., 1996) levels of nitric oxide in migraine sufferers 
have been shown. Abnormalities in nitric oxide signaling pathway and increase in activity 
of nitric oxide synthase has been shown to be associated with enhanced susceptibility to 
migraine (Olesen, 2008). The oral administration of nitroglycerin as a nitric oxide donor 
induces headaches, which resembles to spontaneous migraine attacks. Also, in migraineurs, 
nitroglycerine inhibitors attenuated these nitroglycerin-induced attacks (Olesen, 2008) and 
as a result nitric oxide is suggested as fundamental biomarker for migraine (Loder et al., 
2006). According to this point of view, nitric oxide is thought to be central in the 
pathophysiology of migraines. It seems likely that nitric oxide functions as the modulator of 
cellular toxicity, inflammatory responses, release of calcitonin gene related peptides as a 
potent peptide vasodilator, platelet function, endothelium-dependent vasodilatation, and 
transmission of pain impulses (Olesen, 2008).  
2.2.3.5 Cations 
Although, elements have been excluded from metabolome and proteome subclass, their 
strong connection with biomarkers cannot be ignored. The cations play a key role in 
cerebrospinal fluid functions and change in their serum levels is associated with 
pathogenesis of several diseases such as migraine headache (Donma & Donma, 2002). 
Considering the role of mutation in sodium, calcium and sodium-potassium channels in 
familial hemiplegic migraine, cations are important in migraine pathogenesis (Harrington et 
al., 2006). Moreover, nowadays, calcium channel blocker drugs are being used in migraine 
treatment, more extensively (Goadsby & Sprenger, 2010).  
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It seems that magnesium has a greater role as a possible biomarker of migraine, than other 
elements (Loder et al., 2006). It has been reported that serum magnesium concentration 
decreases in patients with migraine (Roudbari et al., 2005; Sun-Edelstein & Mauskop, 2009). 
Clearly, decreased magnesium concentration can trigger migraine attack (Mauskop, 1998), 
probably by promoting cortical spreading depression; alteration in neurotransmitter release 
and platelet hyperaggregation (Sun-Edelstein & Mauskop, 2009). The blockage of serotonin 
receptor and/or inducible receptor of glutamate, NMDA, and inhibition of synthesis and 
release of nitric oxide are believed to be of great physiological importance of magnesium 
(Sun-Edelstein & Mauskop, 2011). 
According to the results of a study, increase in cerebrospinal fluid sodium concentration, 
independently from other clinical or pharmacological fluctuations of other cations, can 
participate in pathogenesis of migraine with aura. It is probable that concomitant elevated 
sodium concentration and normal cerebrospinal fluid potassium concentration, partially can 
decrease resting membrane potential and lead to decrease of action potential threshold in 
patients with migraine (Harrington et al., 2006). It has been suggested that salt out acts as 
potential migraine trigger (Brainard, 1976). 
2.2.3.6 Others 
Despite the importance of mentioned biomarkers in migraine pathology, several studies 
have reported changes in level of other biochemical biomarkers such as S100┚, a glia-
derived cytokine (Papandreou, 2005), dopamine and dopaminergic system (Charbit et al., 
2010), endothelin-1 (Kallela et al., 1998), excitatory neurotransmitters such as glutamate and 
substance P, and pain-related molecules such as met-enkephalin and β-endorphin 
(Harrington, 2006) in/or between migraine attacks. 
2.2.4 Practical considerations  
There are some notable issues about mentioned biomarkers: (i) several of these biomarkers 
have potential interactions with others and have influences on concentration of other 
biomarkers. For example, melatonin as an imperative antioxidant is considered to be 
scavenger of nitric oxide and its toxic metabolite peroxynitrite (ONOO-) from body. 
Additionally, melatonin can indirectly lead to decrease in nitric oxide synthase activity and 
expression in body (Acuña-Castroviejo et al., 2005); (ii) Results of measurement of a 
biomarker from two separate samples can be different. For example the concentration of 
melatonin in urine of patients with migraine is more valuable than its plasma concentration. 
As a result, assessment of concentration of urine and plasma melatonin were considered as 
confirmed and probable biomarker, respectively (Loder et al., 2006), and (iii) the levels of 
some these biomarkers in each person or in each attack are not varied similarly, therefore it 
seems that contemporary investigation of proteome or metabolome profile in migrainous 
patients, as has been employed for other conditions such as cancer (Casado-Vela et al., 2011), 
is necessary. 
Despite of wide-ranging list of migraine biomarkers which has been described; it is believed 
that a complete assessment of clinical features and signs, and careful history taking may be 
decisive in the migraine diagnosis and these biomarkers, mainly genetic ones, “will be a test, 
not the mere identification of a marker, which will change clinical practice.”(Goadsby, 2006). 
Nevertheless, migraine symptoms appeared to vary not only in each person but also in each 
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attack. It is noted that after taking a medical history from a patient, one should be sure about 
absence of any other common headache in this context. To support this diagnosis, a series 
complementary tests including genetic and biochemical markers appears to be useful. Also, 
nowadays, instead of treatment of migraine based on pathological mechanisms, it is focused 
on clinical symptoms. It is evident that current treatments relieve migraine attacks slowly. 
Treatment strategies based on biomarkers can help us in this field. For example, if a 
biomarker reaches to normal level or diminishes, it is possible that the choice of the strategy 
for treatment is successful and/or the patients don’t require further treatments. In addition, 
the investigation about cause of changes in biomarker levels can help us to explore 
mechanism and underlying environmental factors that trigger migraine. Also, it can be 
helpful in differentiation of migraine diagnosis (Loder, 2006). 
2.3 Trigger factors in migraine 
Any factor, that on exposure or withdrawal, alone or in combination, leads to the 
development of an acute migraine headache, is known as migraine trigger (V.T. Martin & 
Behbehani, 2001). They also are called precipitating or provoking factors that usually 
happen before the attack by less than 48 hours (P.R. Martin, 2010). These triggers can be 
categorized into two identifiable groups: internal and external (V.T. Martin & Behbehani, 
2001). Based on twin studies, observed concordance rate for migraine headache in mono- 
and dizygotic twins are 37-52% and 15-21%, respectively. The fact that concordance rate for 
migraine in monozygotic twins is not 100%, suggests that environmental factors contribute 
to the development of migraine headache (V.T. Martin & Behbehani, 2001). 
2.3.1 External triggers 
External triggers that we hear most often about them, can be classified broadly as 
environmental, behavioral, dietary, chemical, allergens and some drugs (V.T. Martin & 
Behbehani, 2001) of which some are listed in Table 1. Stress is the most commonly 
mentioned migraine trigger, and it seems that can initiate or augment frequency and 
severity of migraine attack (Hauge et al., 2009; Millichap & Yee, 2003). Most information 
about prevalence of triggers has been reported in population- or clinical- based studies in a 
self-report manner by patients own experience which could lead to a significant bias. These 
studies didn’t have the technical or methodological strength and the results are variable and 
contradictory (P.R. Martin, 2010; V.T. Martin & Behbehani, 2001) and more discussion about 
the epidemiological studies on external triggers are not necessary, as well. 
2.3.1.1 Possible mechanisms  
An understanding of the aura and headache components of migraine provides a basis for 
the potential mechanism of action of dietary triggers. Theoretically, migraine triggers could 
influence on the cerebral cortex, organizations innervated by the terminal nerve (i.e. dural 
arteries), the trigeminal pain pathway (trigeminal nerve, thalamic nuclei), and regulatory 
pathway within the brain stem or the limbic system contribute to migraine. Therefore, 
migraine triggers aggravate migraine headache in a number of diverse ways, including: (i) 
direct effect on excitatory or inhibitory neuroreceptors; (ii) release of internal neuropeptides 
or neurotransmitters and nitric oxide; and (iii) direct excitation of neurons (V.T. Martin & 
Behbehani, 2001; Millichap & Yee, 2003).  
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Dietarya   
 Caffeinated beverages 
 Alcoholic beverages 
 Aged cheeses 
 Chocolate 
 Coffee, tea, cola 
 Chocolate  
 Food allergens (Dairy products, 
yogurt) 
 Ice cream 
Chemicala  
 Monosodium glutamate 
 Tyramine 
 Nitrates 
 Artificial sweetener (Aspartame) 
Environmentalb 
 Bright light/visual stimuli 
 Odors/smells 
 Weather changes 
 Cigarette smoke 
Behavioralb  
 Stress/tension 
 Hunger/not eating 
 Emotions 
 Lack of sleep and Sleeping late/excess 
 Fatigue/tiredness 
 Exercise 
 Hair wash or head bathc 
 
Minor head traumad 
a(V.T. Martin & Behbehani, 2001; Millichap & Yee, 2003); b(P.R. Martin, 2010; V.T. Martin & Behbehani, 
2001); c Reported in Indian patients (Ravishankar, 2006), d Frequently reported as a trigger for 
hemiplegic migraine (Russell & Ducros, 2011) 
Table 1. External Trigger Factors in Migraine. 
2.3.2 Internal triggers 
Internal triggers are those that occur in our body. The most common internal triggers are sex 
hormones (neurosteroids and ovarian steroids). The key stages of reproduction including first 
menstruation, pregnancy and menopause are associated with frequency or severity of 
migraine. It is suggested that sex steroids (i.e. estradiol and progesterone) have a central role in 
migraine etiology (Gupta et al., 2007; V.T. Martin & Behbehani, 2006b) especially in menstrual 
migraine. 35-51% of female migraineurs have menstrually related migraine, even though 7-
19% has pure menstrual migraine. Interestingly only attacks of migraine without aura occur 
during the perimenstrual time period and attacks of migraine with aura happen equally 
during the menstrual cycle. The main trigger of menstrual migraine seems to be withdrawal of 
estrogen rather than the maintenance of continuous high or low estrogen levels. On the other 
hand, sustained changes in estrogen levels related to pregnancy (augmented levels) and 
menopause (declined levels) likewise affect headaches (V.T. Martin & Behbehani, 2006b).  
2.3.2.1 Possible mechanisms  
The neurosteroids and ovarian steroids may exert their effects on vascular and nervous system 
via cytosolic and nuclear receptors (genomic pathway) and membrane receptors (non-genomic 
pathway) and initiate a migraine attack (V.T. Martin & Behbehani, 2006a). These steroids can 
lead to neuronal excitation via increase in calcium and decrease in magnesium concentration, 
vasodilatation and activation of trigeminal nerve through synthesis and release of nitric oxide, 
neuropeptides (i.e. calcitonin gene related peptide), increase or decrease in inhibitory or 
excitatory neurotransmitters synthesis and opioids and their impacts on receptors. However 
there are some contradictory results of negative or positive effects of steroids on onset of 
migraine attack (Gupta et al., 2007; V.T. Martin & Behbehani, 2006a). 
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2.3.3 Genetic background 
Any change in activity of involved gene in hormonal and vascular function causes increase 
in susceptibility to migraine. Recently, it has been suggested that the association between 
migraine and dysfunction of genes involved in progesterone and/or estrogen receptor 1, 
might play a role in increased susceptibility to migraine (Colson et al., 2006). Moreover, 
diamine oxidase activity in histamine breakdown in the intestine might be important in 
those who are sensitive to food containing histamine. It seems that vitamin B6 
supplementation enhances diamineoxidase activity, and in that way decreases histamine-
induced migraine attacks (Ross, 2011). 
3. Treatment 
Introducing the concept of brain disorder in migraine etiology led to a new approach in 
treatment options in migraine disorder (Monteith & Goadsby, 2011). Migraine treatment can 
be classified into medical and non-medical treatment. Non-medical treatments include 
patient education and behavioral therapy for the prevention of trigger factors involved in 
migraine. The pharmacotherapy for migraine can be categorized into preventive drugs, 
which are administrated daily regardless of the presence of headache and acute drugs, 
which are taken by patients immediately after symptoms appearing (Goadsby et al, 2002).  
3.1 Drugs 
Acute treatment is classified into nonspecific treatments, including non-steroidal anti-
inflammatory drugs (NSAIDs), and migraine-specific treatments, including ergot 
derivatives and the triptans (Table 2) (Goadsby et al, 2002). However, only one third of 
patients in clinical trials feel pain-free 2 hours after taking a triptan orally, so novel 
treatment options are still required. Recently, new drugs have been developed by targeting 
neural sites. Interestingly, safety and efficiency of some of these drugs have been confirmed 
in phase II and some other in phase III clinical trials (Monteith & Goadsby, 2011). 
Preventive therapy (prophylaxis) including beta-blockers, anticonvulsants like valproate and 
topiramate, and calcium channel blockers are preferred choice for treatment of patients 
unresponsive to acute-attack medications (Table 2). In the U.S, therapeutic guidelines regular 
migraine prophylaxis for patients with more than two acute attacks per week are 
recommended, but in the Europe the regular preventive treatment therapeutic guidelines are 
recommended on the basis of two or more acute attacks per month (Goadsby & Sprenger, 2010). 
3.2 Complementary alternative medicine 
Despite some controversy regarding formal definition for Complementary Alternative 
Medicine, the National Center for Complementary and Alternative Medicine, defines it as “a 
group of diverse products, medical and health care systems, practices that are not presently 
considered to be part of conventional medicine.” Using complementary alternative medicine 
along with conventional medical treatments as part of a multidisciplinary treatment strategy 
has higher probability to result in appropriate responses. Although, some evidences are 
available in favor of these treatments, more extensive studies are required to fully elucidate 
their efficacies (Sun-Edelstein & Mauskop, 2011). Here nutritional supplements and 
medicinal herbs will be explained further. 
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Acute attack drugs in migrainea 
Specific drugs 
 Ergot derivatives 
 (ergotamine and dihydroergotamine) 
 Serotonin 5-HT receptor agonists 
 5-HT1B/1D receptor agonists  
 Triptans: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, 
Sumatriptan, and zolmitriptan. 
 Serotonin 5-HT1F receptor agonists* 
 Other receptors antagonists*  
 Calcitonin gene-related peptide (Olcegepant and telcagepant) 
 Glutamate AMPA/kainate  
 Transient receptor potential vanilloid-1 
 Prostanoid EP4 
 Inducible and neuronal nitric oxide synthase inhibitors* 
Nonspecific drugs 
 Non-steroidal anti-inflammatory drugs (Aspirin, acetaminophen),  
 Opiates, and combination analgesics 
Preventive drugs in migraineb 
 Beta-blockers  (Propranolol, Metoprolol)  
 Anticonvulsants (Valproate, Topiramate) 
 Calcium channel blockers (Flunarizine) 
 Antidepressants (dosulepin (dothiepin), Venlafaxine) 
 Serotonin antagonists (Pizotifen, Methysergide) 
 ACE inhibitors (Lisinopril, Candesartan) 
 Cortical spreading depression inhibitors (tonabersat) *  
 Neuromodulators (the stimulation of the greater occipital nerve) * 
 Botulinum toxin type-A*  
 Patent foramen ovale closure* 
* These drugs are under investigation in phase II or III clinical trial. a(Goadsby et al., 2002;  Goadsby & 
Sprenger, 2010; Monteith & Goadsby, 2011); b(Goadsby & Sprenger, 2010). 
Table 2. Acute and preventive drugs for migraine treatment. 
3.2.1 Riboflavin 
Riboflavin (vitamin B2) is critical for membrane stability, cellular energy production and the 
maintenance of cellular functions (Rios & Passe, 2004; Sun-Edelstein & Mauskop, 2009). It is 
thought a deficit in brain mitochondrial energy reserve, causes biochemical changes that trigger 
the trigeminovascular system, and therefore play an important role in migraine attacks (Rios & 
Passe, 2004). Riboflavin can increase the mitochondrial energy efficiency. It is reported an 
attenuation of the frequency of migraine attack after supplementation with high dose riboflavin 
(400 mg/day) for three months (Sun-Edelstein & Mauskop, 2009) (Rios & Passe, 2004). Despite 
minor side effects of high-dose of riboflavin (including diarrhea and polyuria), no identified 
complication is reported for riboflavin in pregnancy (Rios & Passe, 2004). However, there is no 
consensus that riboflavin is to significantly operative in migraine preventive. 
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3.2.2 Coenzyme Q10 
Due to its function on mitochondrial respiratory chain and antioxidant activity, it seems 
to be helpful to prevent migraine (Sun-Edelstein & Mauskop, 2009; 2011). Moreover, 
efficacy of coenzyme Q10 supplementation in migraine pediatric prophylaxis has been 
reported (Ross, 2011; Sun-Edelstein & Mauskop, 2009; 2011) and approximately 300 mg of 
coenzyme Q10 is thought to be effective in migraine prevention (Sun-Edelstein & 
Mauskop, 2009). However, these results require further approval before to be suggested 
as an effective treatment.   
3.2.3 Alpha-lipoic acid 
Similar to riboflavin and coenzyme Q10, alpha-lipoic acid improves oxygen metabolism in 
mitochondria and adenosine triphosphate production (Sun-Edelstein & Mauskop, 2011). 
Although no defined supplementation dose for alpha-lipoic acid have been approved by the 
U.S Food and Drug Administration, it is reported that supplementation with 600 mg of 
alpha-lipoic acid once a day for three months attenuated the frequency of migraine attacks 
(Sun-Edelstein & Mauskop, 2009).  
3.2.4 Magnesium 
Based on results of several investigations, failure in calcium-magnesium balance in 
patients with migraine plays a key role in pathogenesis of this disease. In addition to 
possible role of magnesium as a biomarker for migraine (described previously), 
regarding its physiological functions in energy production, maintaining blood vessel 
tone and stability of neurons, it may be beneficial in patients with migraine (Ross, 2011; 
Sun-Edelstein & Mauskop, 2009; 2011). Although oral magnesium can prevent migraine 
attacks and intravenous magnesium can reduce acute headache, the use of magnesium 
has shown controversial results (Sun-Edelstein & Mauskop, 2009; 2011). The daily 
supplementation with 400 mg of chelated magnesium (Sun-Edelstein & Mauskop, 2009), 
magnesium oxide or 600 mg of trimagnesium dicitrate (Rios & Passe, 2004) is thought to 
be effective in treatment of migraine. These remarks have not been confirmed yet. The 
high dose of magnesium can cause diarrhea, loss of appetite, nausea, vomiting and 
gastric irritation. Also, owing due to involvement of high dose of magnesium in 
decreasing fluoroquinolones absorption, it is not recommended for patients with 
ulcerative colitis, diverticulitis, or renal failure and in pregnant or nursing women (Rios 
& Passe, 2004). 
3.2.5 Dietary avoidance 
Elimination of food allergens (including cow’s milk; wheat; eggs) (Ross, 2011) or dietary 
triggers (described in external triggers previously) (V.T Martin & Behbehani, 2001; Millichap 
& Yee, 2003), which initiate a migraine attack, can lead to elimination or reduction of 
frequency and severity of migraine attacks. Thus, they can be considered as candidate for 
treatment of migraine. Though, due to daily need to some of the mentioned foods for 
cellular function, it is impossible to eliminate them from dietary completely, so they are 
replaced with either (Millichap & Yee, 2003).  
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4. Herbal medicine 
4.1 History  
Before the advent of modern synthetic drugs, herbs were considered as first choice for 
treatment of human diseases. In spite of the fact that using herbs has been diminished in 
modern medicine, fortunately, there is a growing trend, particularly in migraine disorder. 
There have been few studies examining herbal remedy effectiveness and most of our 
information is based on traditional experiences. However, mechanism of action of many of 
them have not been fully understood.  
In traditional medicine in Iran, China and India and some older societies, factors such as 
geographic location and experience in the proven effectiveness of herbs, affect their 
acceptance as medicine. The famous scientists gathered their ancestor's experiences and 
their own researches which remained as useful references for the future. Qanoon fel teb 
(The Canon of Medicine) by Ebn-e-Sina (Avicenna, 980–1037), al-hawi (Continens) by Zakariya 
Râzi (Rhazes, 860–940) and Kitab-al-Maliki (Liber Regius) by Ali Ebn Al-Abbas-al-Majusi 
(Haly Abbas, 949–982) are good examples in this regard (Gorji, 2003; Gorji & Khaleghi 
Ghadiri, 2002). On the other hand, using new techniques to analyze the active 
ingredients of plants and methods for the study of underlying mechanism, can confirm 
their effectiveness and safety. Due to the easier and faster access to medical information 
resources of traditional medicine for treatment, as well as new technology in various 
countries to identify the mechanism of action of herbal ingredients, it is possible to 
clarify more aspects of mechanism underlying treatment of several diseases, such as 
migraine.   
4.2 Herbs application for migraine treatment  
4.2.1 Analgesic effects 
Analgesics are widely used for pain relief worldwide. Many herbal remedies have been 
proved to be effective in painful situations like migraine headache empirically and/or in 
clinical trials. Some of these botanical analgesics which have shown pain killing effects are 
listed in Table 3 (Yarnell, 2002; Zareba, 2009; Zengion & Yarnell, 2011). Although some 
aspects of herbs mechanism of action have been understood, more studies are required to 
elucidate anodyne herb’s function.  
Herbs containing salicylates and those with anti-inflammatory effects are usually safe and 
beneficial for pains caused by inflammation (Yarnell, 2002; Zareba, 2009; Zengion & Yarnell, 
2011). Salix alba is a good example which decreases pain due to its salicin content and is 
reported for migraine treatment (Gorji, 2003; Gorji & Khaleghi Ghadiri, 2002). Feverfew and 
ginger (Mustafa & Srivastava, 1990) are two important anti-inflammatory herbs with proved 
anti-migraine activity. Hypnotic anodynes have more general analgesic properties and are 
ideal when pain contributes to insomnia. Some studies recommended Valerian to be used in 
migraine treatment. Numerous centrally-acting herbs have stronger analgesic effect and 
they should be used with lower doses to avoid adverse effects. Topically used herbs like 
Capsicum frutescens could propose a useful way to relieve neuropathic pain, and other pain 
syndromes due to capsaicin as an effective component. Intranasal application of capsaicin 
for relief of migraine is reported (Yarnell, 2002). 
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Anti-inflammatory herbs   
 Curcuma Longa (Turmeric)  
 Angelica sinensis (Dang Gui, Tang Kui, 
Dong Kuai),  
 Harpagophytum procumbens (Devil’s 
Claw)* 
 Boswellia serrata (Frankincense)* 
 Zingiber officinalis (Ginger)*  
 Tanacetum parthenium (Feverfew)* 
Centrally-acting herbs  
 Cannabis sativa (Cannabis)* 
 Hypericum perforatum (St. John’s Wort)* 
 Corydalis yanhusuo 
 Bryonia alba (White Bryony)  
Hypnotic herbs 
 Valeriana officianalis (Valerian)* 
 Piscidia piscipula, P. erythrina (Jamaican 
Dogwood) 
 Eschscholtzia californica (California Poppy) 
Salicylate-containing herbs  
 Salix alba (White Willow)* 
 Populus tremuloides (Quaking Aspen) 
Topical herbs  
 Capsicum frutescens (Cayenne)* 
 Urtica dioica (Stinging Nettle) 
 Symphytum officinale (Comfrey) 
Miscellaneous 
 Ginkgo biloba (Ginkgo)* 
 Centella asiatica (Gotu Kola) 
 Viburnum opulus (Cramp Bark) 
 Viburnum prunifolium (Black Haw) 
 Scutellaria laterifolia (Skullcap) 
 Scutellaria baicalensis (Huang qin) 
 Rosa canina* 
 Solidago chilensis (Brazilian Arnica) 
 * analgesic herbs which are traditionally used for relief of migraine headache (Gorji, 2003; Gorji & 
Khaleghi Ghadiri, 2002; Yarnell, 2002; Zareba, 2009)..  
Table 3. Analgesic herbs used for pain relief (Yarnell, 2002; Zareba, 2009; Zengion & Yarnell, 
2011). 
4.2.2 Prophylactic effects 
Efficacy for prophylactic drugs is defined as a reduction in migraine frequency of more than 
50%. Also it could refer to reduction in attack severity, or significant reductions in nausea, 
vomiting, photophobia and phonophobia. Feverfew and butterbur were the first herbs that 
have been utilized for migraine preventive therapy. 
4.2.2.1 Feverfew  
Although, feverfew (Tanacetum parthenium) is a perennial herb native to Balkan Mountains 
in Eastern Europe, in more recent times it has become naturalized widely in Europe, North 
America, and South America (Sun-Edelstein & Mauskop, 2011). Several studies have been 
reported that feverfew has anti-inflammatory and anti-platelet aggregation properties, 
thereby having promising results in the treatment of migraine (Rios & Passe, 2004; Ross, 
2011). Its anti-migraine action is probably related to its active compound i.e. parthenolide 
(Sun-Edelstein & Mauskop, 2011). Although optimal supplementation dose have not been 
established, daily supplementation with 100 mg (Sun-Edelstein & Mauskop, 2009) or 50-145 
mg of feverfew supplements, containing at least 0.2% parthenolide (Rios & Passe, 2004; 
Ross, 2011) is thought to be effective in migraine treatment. The usage of these doses is 
associated with side effects like nausea, and diarrhea, mouth ulcerations (only when 
chewing leaves), and withdrawal symptoms including muscle stiffness, anxiety, and 
rebound migraine headache. It is noted that the use of feverfew supplements is not 
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recommended in pregnancy (due to uterus contraction), nursing women, children below 2 
years, patients with high sensitivity to plants of Asteraceae family (Rios & Passe, 2004; Ross, 
2011), and patients undergoing surgery, due to its function as an inhibitor of platelet 
aggregation (Ross, 2011).Using feverfew as an approved medication require further 
investigations. 
4.2.2.2 Butterbur  
Butterbur (Petasites hybridus) also known as pestwurz, blatterdock, bog rhubarb, and butter-
dock (Rios & Passe, 2004), is an herb, found throughout Europe and parts of Asia (Sun-
Edelstein & Mauskop, 2011). It seems to be a promising drug for reduction of frequency and 
severity of migraine attacks (Rios & Passe, 2004; Ross, 2011), especially in children (Oelkers-
Ax, et al., 2008). Butterbur is rich in pharmacologically active compounds called 
sesquiterpenes; such as petasin and isopetasin (Sun-Edelstein & Mauskop, 2011). Despite 
uncertainty about its optimal dose, similar to feverfew, by Food and Drug Administration 
(Rios & Passe, 2004), 75 mg of butterbar twice daily for a month, following 50 mg twice a 
day (Sun-Edelstein & Mauskop, 2009) or 50-100 mg twice a day, containing at least 7 mg of 
petasin and isopetasin (Rios & Passe, 2004) is believed to be beneficial for migraine 
headaches. So, until performing further studies, it cannot be supported as an effective 
treatment for migraine. Pyrrolizidine alkaloids found in butterbur are recognized as toxins 
with carcinogenic and hepatotoxic effects. For this reason, it is necessary to eliminate these 
alkaloids from commercial butterbur extracts (Sun-Edelstein & Mauskop, 2011). It is not 
recommended for the pregnant or nursing mothers (Rios & Passe, 2004). 
4.2.2.3 MigriHeal®  
Recently a novel herbal remedy was introduced with prophylactic effect against migraine 
attacks which lasts even after the discontinuation of therapy (Fallah et al., 2005). This herbal 
drug which is used as inhalation up to 4 months can decrease headache frequency and 
severity (www.araamesh.com). No adverse effects were reported by patients and animal 
study proved its safety even in higher doses. Investigating the effect of MigriHeal® extracts 
on nitric oxide production in mouse endothelial cell-line showed reduced production in a 
dose-dependent manner (Ansari et al., 2005; 2007). 
4.3 Possible mechanisms of medicinal herbs used in migraine 
On the contrary to primary products, such as carbohydrates, lipids, proteins, heme, 
chlorophyll, and nucleic acids, which participate in modulation of cellular  metabolism and 
maintenance of plant cells, the benefits of phytomedicine typically may be caused by the 
combined action of secondary plant compounds. Although, up to now, there are some in 
vivo and in vitro studies about role of phytomedicine in migraine treatment as well as its 
possible mechanism, further investigation is required. Therefore, studies exploring the effect 
of phytomedicine on frequency and severity of migraine attacks can help us to understand 
the etiology of migraine. Besides, investigation of plant derivatives can lead to new drugs 
for migraine treatment.  
Here, we discuss possible mechanisms of several medicinal plants, used in migraine 
headache treatment. 
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4.3.1 Compensatory components   
Due to high level of some molecules in medicinal plants, which are reduced in patients with 
migraine, it seems that they can be used as compensatory mechanism for migraine 
treatment. It has been shown that some medicinal plants including Tripleurospermum 
disciforme, Viola odorata and Tanacetum parthenium used in treatment of migraine headache, 
contain high concentration of melatonin (Ansari et al., 2010). Notably, these results are in 
line with other studies about other medicinal plants used in treatment of neurologic 
disorders, Tanacetum parthenium, Hypericum perforatum, and Scutellaria biacalensis (Murch et 
al., 1997) and Chinese medicinal plants  are used in treatment oxidative abnormality-related 
diseases (Chen et al., 2003). Plasma level of melatonin is decreased in migraine and its 
therapeutic use in this disorder has been reported (Peres et al., 2006). In the other hand, 
owing to increase in plasma concentration of melatonin in human (Oba et al., 2008) and rat 
(Reiter et al., 2005) following phytomelatonin administration, the high content of melatonin 
(from picograms to micrograms per gram of plant material) in these medicinal plants is 
thought to be responsible of reduction of migraine attack and can be considered as potential 
candidate for migraine prevention. 
Interestingly, In vivo studies have been shown that extract of some medicinal plants can 
enhance gene expression and activity of enzyme involved in melatonin synthesis, N-
acetyltransferase, thereby increasing melatonin level (Qu et al., 2008). In addition, it seems 
that the extract of some plants has large affinity for the serotonin (5-HT4e, 5-HT6, and 5-HT7) 
and melatonin (ML1 and ML2) receptors (Abourashed et al., 2004). In spite of some 
discrepancies between the studies on role of enzymes involved in melatonin synthesis and 
melatonin receptors in migraine etiology, the involvement of melatonin in migraine 
pathogenesis is notable. Accordingly, further studies are required to elucidate possible 
impact of medicinal plants on reduction or treatment of migraine attacks as well as 
underlying mechanism.  
In addition of melatonin, high level of several metabolites of tryptophan metabolism 
including 5-Hydroxytryptophan, as a direct precursor of the neurotransmitter serotonin, 
(used to boost levels of this compound in the human brain thereby treating cases of 
serotonin deficiency syndrome) (Lemaire & Adosraku., 2002), tryptamine and serotonin 
(Badria, 2002) have been considered in some medicinal plants. It seems that the metabolites 
will be a potent term in phytomedicine research reports, particularly in migraine treatment. 
4.3.2 Effects on signaling and expression regulation 
4.3.2.1 Effects on nitric oxide formation and calcitonin gene related peptide 
These effects can result from elimination of nitric oxide, inhibition of gene expression of 
enzymes and removal of calcium ion from environment and its influence on calcium 
channels and calcitonin gene related peptide. For example, some medicinal plants such as 
Lavender, Coriander, Chamomile and Viola can decrease nitric oxide as stated in Ansari et 
al. report. There have been noted that different forms (e.g. aqueous extract, essential oil) of 
these herbs significantly suppress nitric oxide production in a dose-dependent manner 
(Ansari et al., 2005; 2007) and possibly thereby reducing migraine attacks. These herbs with 
analgesic and/or prophylactic effects are also summarized in Gorji et al. reviews (Gorji, 
2003; Gorji & Khaleghi Ghadiri, 2002). 
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It is believed that the parthenolide as a sesquiterpene lactone in feverfew prevents migraine. 
The parthenolide has been found to inhibit, lipopolysaccharide-induced nitric oxide 
formation and lipopolysaccharide-induced activation of the inducible isoform of nitric oxide 
synthase. It should be noted that several flavonoid glycosides in feverfew have shown 
vasodilation and anti-inflammatory properties, but parthenolide in other plants have not 
shown anti-migraine effects. Interestingly, extract with high parthenolide showed a low 
tolerability, in comparison with purified parthenolide. 
Treatment of rat trigeminal ganglia cultures with Theobroma cacao extract, following 
exposure to depolarizing stimuli was shown to block calcium channel activity and to 
inhibit the HCl and capsain-stimulated enhancement in calcitonin gene related peptide 
secretion. According to in vivo study, this extract was demonstrated to decrease nitric 
oxide release and inflammatory cytokines from macrophages significantly (Abbey et al., 
2008). Nutritional coca in a similar manner, can suppress calcitonin gene related peptide 
expression in neurons and inducible nitric oxide synthase activity, thereby it is involved 
in migraine pathophysiology, pain feeling and inflammation-related responses. 
Interestingly, cocoa can suppress neuronal increased expression of the mitogen-activated 
protein kinase p38 and extracellular signal-regulated kinases after stimulation with acute 
or chronic peripheral inflammation (Cady & Durham, 2010). It is noted that mitogen-
activated protein kinase signal transduction participated in initiation and stimulation of 
inflammatory responses and pain feeling. It has been suggested that high level of 
borocyanides in Arace catechu as well as inhibitory influence on inducible nitric oxide 
synthase activity can be involved in its underlying mechanism in anti-migraine properties 
(Bhandare et al., 2011). 
4.3.2.2 Effects on Arachidonic pathway 
The feverfew (parthenolide) is known to inhibit prostaglandin, thromboxane B4 and 
leukotriene B4 release by phospholipase A2 inhibition (Summer et al., 1992). Main active 
ingredients of butterbur are petasin and isopetasin, inhibiting both lipoxygenase pathway 
and leukotriene synthesis –related anti-inflammatory effects (Rios & Passe, 2004; Ross, 
2011). On the other hand, the inhibitory properties of ginger in prostaglandins, 
thromboxanes and leukotriene have been linked to its anti-migraine effects (Mustafa & 
Srivastava, 1990). 
4.3.2.3 Effects on platelet activity 
Regarding to decrease in platelet 5-hydroxytryptamine content, change in 5-
hydroxytryptamine transport as well as platelet cytosolic free-calcium concentration, in 
patients with migraine, it is evident that abnormalities in platelet function may participate in 
migraine pathogenesis (Rogers et al., 2001). According to results of a study, for  
quantification  of the antiplatelet effect of Australian plants extracts via testing adenosine di 
phosphate induced platelet aggregation and the release of 5-hydroxytryptamine, it has been 
demonstrated that  these extracts  through regulation of cyclooxygenase pathway may 
contribute to inhibition of platelet 5-hydroxytryptamine release (Rogers et al., 2000). 
Previously, Rogers et al reported that E. vespertilio and C. ambiguous can be served as 
traditional treatments for headache due to inhibitory effect of their extracts on platelet 
activation (Rogers et al., 2001). 
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In view of the several studies about function of gingkolide B (an herbal constituent extract 
from Ginko biloba leaves) as a natural antiplatelet activating factor, recently it has been 
shown that its administration can be effective in patients with primary headache (Usai et al., 
2011). Based on investigation of ginsenosides (active constituent of Genus Panax, ginseng) 
effects on rats, it has been shown that they inhibit thrombin or collagen-induced platelet 
aggregation. In addition, it has been reported that enough concentrations of allicin, a 
primary constituent of garlic (Allium sativum) can result into platelet aggregation and 
degranulation blockage. Despite of in vitro studies, it is noted that after administration of 
these plants in healthy individuals, the platelet function does not change (Beckert et al., 
2007).  
On the other hand, goshoyoto as an herbal drug seems to be effective in treatment of 
migraine headaches by suppression of platelet aggregation. Its two herbal components, 
zingiberis and evodiae, have been shown to inhibit collagen-induced platelet aggregation. 
Interestingly, 6-gingerol and 6-shogaol as two constituents of zingiberis can inhibit platelet 
aggregation by inhibition of cyclooxygenase-1 activity (Hibino et al., 2008). In another study, 
anti-migraine properties of Sapindustrifoliatus water extract has been linked to both 
inhibition of 5-HT2B receptor and release of platelet serotonin (Arulmozhi et al., 2004). 
4.3.2.4 Effects on ion channels 
Evidences link the ion channel gene mutations, particularly those encoding voltage-gated 
calcium channels, to rare and severe hemiplegic migraine. Accordingly, use of L-type 
voltage-gated calcium channels blockers for the prophylactic relief of migraine seems 
occasionally reasonable.  Studies show that extracts of E. bignoniiflora, A. symphyocarpa and E. 
vespertilio have potential antagonists of neuronal voltage- gated calcium channels (Rogers et 
al., 2002). In addition, due to combined effects of Cav2.1-inhibitory properties of petasins (as 
the main constituents of the anti-migraine herb P. hybridus) and sulfur containing petasins in 
these herbs, it can be considered as appropriate approach to migraine prophylaxis (Horak et 
al., 2009). These findings prompt further electrophysiological studies to investigate the 
modulatory capacity of these compounds on other ion channels implicated in hemiplegic 
migraine pathophysiology. 
4.3.2.5 Others 
In addition to mentioned mechanism underlying the effect of herbal medicine in migraine 
treatments, several pathways is thought to be involved in this regard. For example, based on 
results of one study (Arulmozhi et al., 2005), it has been suggested that the high level of 
saponin in Sapindus trifoliatus can have a regulatory role in dopaminergic and adrenergic 
receptors. Also, anti-inflammatory, analgesic and narcotic properties of this herb can be 
responsible for its effects in migraine treatment. It is worth mentioning that these receptors 
can associate with migraine pathogenesis. 
5. Conclusion 
It seems that future researches should be emphasized to unravel the hidden area of migraine 
pathophysiology using metabolomics and proteomics study which could also lead to find 
some biomarkers to discriminate patient and healthy people. The latter could be used in 
new classification of the disease, and also as a strong diagnostic tool. 
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